Journal Article
. 1997 Jun; 336(25):1776-80.
doi: 10.1056/NEJM199706193362502.

Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia

L C Hartmann 1 L K Tschetter  T M Habermann  L P Ebbert  P S Johnson  J A Mailliard  R Levitt  V J Suman  T E Witzig  H S Wieand  L L Miller  C G Moertel  
Affiliations
  • PMID: 9187067
  •     35 citations

Abstract

Background: Randomized trials of colony-stimulating factors in febrile patients with neutropenia after chemotherapy have not consistently shown clinical benefit. Nevertheless, the use of colony-stimulating factors to treat patients with chemotherapy-induced neutropenia is widespread.

Methods: We performed a randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor (G-CSF) in afebrile outpatients with severe chemotherapy-induced neutropenia. We measured the number of days of neutropenia, rate of hospitalization, number of days in the hospital, number of days the patient received parenteral antibiotics, and number of culture-positive infections.

Results: We randomly assigned 138 patients to receive G-CSF (n=71) or placebo (n=67). The median time to an absolute neutrophil count of at least 500 per cubic millimeter was significantly shorter for patients who received G-CSF (two days, vs. four days for the patients given placebo). However, there was no effect on the rate of hospitalization, number of days in the hospital, duration of treatment with parenteral antibiotics, or number of culture-positive infections.

Conclusions: Routine therapeutic application of G-CSF in afebrile patients with severe neutropenia can reduce the duration of neutropenia, but this does not appear to provide practical clinical benefit.

[Use of G-CSF (Neupogen) in multimodal treatment in radiotherapy].
O Bartzsch, M Riepl, +7 authors, M Molls.
Strahlenther Onkol, 1998 Nov 27; 174(11). PMID: 9830435
Review.
[Febrile neutropenia: practical aspects].
P Harten, B Seyfarth, N Schmitz.
Med Klin (Munich), 1998 Dec 16; 93(10). PMID: 9849051
Review.
Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancer.
G Dranitsaris.
Pharmacoeconomics, 2000 Jan 06; 16(4). PMID: 10623363
Review.
Macrophage colony-stimulating factor prevents febrile neutropenia induced by chemotherapy.
T Hidaka, M Fujimura, M Sakai, S Saito.
Jpn J Cancer Res, 2001 Nov 21; 92(11). PMID: 11714451    Free PMC article.
Macrophage colony-stimulating factor (M-CSF) prevents infectious death induced by chemotherapy in mice, while granulocyte-CSF does not.
Takao Hidaka, Masaki Fujimura, +5 authors, Shigeru Saito.
Jpn J Cancer Res, 2002 May 03; 93(4). PMID: 11985793    Free PMC article.
Filgrastim in patients with neutropenia: potential effects on quality of life.
Gary H Lyman, Nicole M Kuderer.
Drugs, 2002 Dec 14; 62 Suppl 1. PMID: 12479595
Review.
The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.
Der-Cherng Liang.
Paediatr Drugs, 2003 Sep 27; 5(10). PMID: 14510625
Review.
Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia.
Marc Esser, Helmut Brunner.
Pharmacoeconomics, 2004 Jan 31; 21(18). PMID: 14750898
Systematic Review.
Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort.
Xianglin L Du, David R Lairson, Charles E Begley, Shenying Fang.
J Clin Oncol, 2005 Nov 30; 23(34). PMID: 16314624    Free PMC article.
Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia.
César Gómez Raposo, Alvaro Pinto Marín, Manuel González Barón.
Clin Transl Oncol, 2006 Nov 01; 8(10). PMID: 17074671
Review.
Economic burden of haematological adverse effects in cancer patients: a systematic review.
S Y Liou, J M Stephens, +3 authors, J W Hay.
Clin Drug Investig, 2007 May 18; 27(6). PMID: 17506589
Systematic Review.
Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients.
Alfredo Carrato, Luis Paz-Ares Rodríguez, +13 authors, Spanish Society of Medical Oncology (SEOM).
Clin Transl Oncol, 2009 Jul 04; 11(7). PMID: 19574202
Cisplatin overdose: toxicities and management.
Roger Y Tsang, Turki Al-Fayea, Heather-Jane Au.
Drug Saf, 2009 Nov 18; 32(12). PMID: 19916578
Review.
Perioperative management for a patient with chronic pancytopenia: a case of aplastic anemia with persistent neutropenia following preoperative administration of G-CSF.
Yoshiko Nakano, Ryu Okutani.
J Anesth, 2010 Jan 23; 24(2). PMID: 20094735
Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia.
Shin Ahn, Yoon-Seon Lee, +5 authors, Kyoo-Hyung Lee.
Support Care Cancer, 2010 Jun 17; 19(8). PMID: 20552376
Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia.
S H Advani, Suvarna Achreckar, Dennis Thomas, Binny Krishnankutty.
Indian J Med Paediatr Oncol, 2011 Jan 06; 31(3). PMID: 21206712    Free PMC article.
A way forward on the medically appropriate use of white cell growth factors.
Thomas J Smith, Bruce E Hillner.
J Clin Oncol, 2012 Mar 01; 30(14). PMID: 22370327    Free PMC article.
Review.
Prediction of docetaxel monotherapy-induced neutropenia based on the monocyte percentage.
Itaru Sato, Naoki Nakaya, +2 authors, Yoshiharu Motoo.
Oncol Lett, 2012 Jun 29; 3(4). PMID: 22741007    Free PMC article.
Retinoid agonist Am80-enhanced neutrophil bactericidal activity arising from granulopoiesis in vitro and in a neutropenic mouse model.
Wanjing Ding, Hiroyuki Shimada, +6 authors, Lingtao Wu.
Blood, 2012 Dec 18; 121(6). PMID: 23243275    Free PMC article.
Febrile neutropenia in hematologic malignancies.
Michael K Keng, Mikkael A Sekeres.
Curr Hematol Malig Rep, 2013 Aug 31; 8(4). PMID: 23990311
Review.
Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan.
Kenichi Harano, Akihiro Hirakawa, +3 authors, Noriyuki Katsumata.
J Gynecol Oncol, 2014 Apr 25; 25(2). PMID: 24761216    Free PMC article.
Granulocyte colony-stimulating factor receptor mutations in myeloid malignancy.
Clifford Liongue, Alister Curtis Ward.
Front Oncol, 2014 May 14; 4. PMID: 24822171    Free PMC article.
Review.
Comments on the mechanisms of action of radiation protective agents: basis components and their polyvalence.
Mikhail V Vasin.
Springerplus, 2014 Aug 19; 3. PMID: 25133093    Free PMC article.
Review.
Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.
Sol Cortés de Miguel, Miguel Ángel Calleja-Hernández, Salomón Menjón-Beltrán, Inmaculada Vallejo-Rodríguez.
Support Care Cancer, 2014 Oct 07; 23(2). PMID: 25284722
Review.
Attitudes and practice patterns for maintaining relative dose intensity of chemotherapy in outpatient clinics: results of a Japanese web-based survey.
Hitomi Sakai, Noriyuki Katsumata, Genmu Kadokura.
BMC Cancer, 2015 Oct 07; 15. PMID: 26438185    Free PMC article.
Am80-GCSF synergizes myeloid expansion and differentiation to generate functional neutrophils that reduce neutropenia-associated infection and mortality.
Lin Li, Xiaotian Qi, +12 authors, Lingtao Wu.
EMBO Mol Med, 2016 Nov 04; 8(11). PMID: 27737899    Free PMC article.
Filgrastim (G-CSF) loaded liposomes: mathematical modeling and optimization of encapsulation efficiency and particle size.
Farhad Kiafar, Mohammad Reza Siahi Shadbad, Hadi Valizadeh.
Bioimpacts, 2016 Jan 01; 6(4). PMID: 28265535    Free PMC article.
[Choosing wisely recommendations in hematology and oncology].
S W Krause, A Neubauer.
Internist (Berl), 2017 May 13; 58(6). PMID: 28497377
Review.
Adequate Neutrophil Responses and Non-Inferior Clinical Outcomes Can Be Achieved by a Two-Day Course of Low-Dose Filgrastim: A Retrospective Single Institution Experience.
Raj Singh, Henry Heisey, Ahmed G Elsayed, Maria T Tirona.
Cureus, 2018 Mar 02; 9(12). PMID: 29492357    Free PMC article.
Increase in short-term risk of rejection in heart transplant patients receiving granulocyte colony-stimulating factor.
Ann B Nguyen, Laura Lourenço, +13 authors, Nir Uriel.
J Heart Lung Transplant, 2018 Sep 04; 37(11). PMID: 30174163    Free PMC article.
Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy.
Hisham Abdel-Azim, Weili Sun, Lingtao Wu.
Pharmacol Ther, 2019 Aug 31; 204. PMID: 31470030    Free PMC article.
Review.
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
Julia Bohlius, Christine Herbst, +2 authors, Andreas Engert.
Cochrane Database Syst Rev, 2008 Oct 10; (4). PMID: 18843642    Free PMC article.
Systematic Review.
Development of an improved murine model of necrotizing enterocolitis shows the importance of neutrophils in NEC pathogenesis.
Michaela Klinke, Deirdre Vincent, +5 authors, Michael Boettcher.
Sci Rep, 2020 May 18; 10(1). PMID: 32415172    Free PMC article.
Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
Nicole Skoetz, Julia Bohlius, +3 authors, Jörg-Janne Vehreschild.
Cochrane Database Syst Rev, 2015 Dec 22; (12). PMID: 26687844    Free PMC article.
Systematic Review.
Chemotherapy induced neutropenia and febrile neutropenia among breast cancer patients in a tertiary hospital in Nigeria.
Omolola Salako, Kehinde Sharafadeen Okunade, +2 authors, Oluwasegun Joshua Afolaranmi.
Ecancermedicalscience, 2021 Mar 30; 15. PMID: 33777181    Free PMC article.